Product News Archives | Page 2 of 13 | Aurobindo Pharma USA

Currently Browsing

All Product News

July 25, 2024


Aurobindo Receives FDA Approval for Doxepin Tablets, 3 mg and 6 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Doxepin Tablets, 3 mg and 6 mg. Aurobindo Pharma’s Doxepin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Silenor Tablets manufactured by Currax Pharmaceuticals LLC. Doxepin Tablets are […]

July 22, 2024


Aurobindo Receives FDA Approval for Baricitinib Tablets, 1 mg and 2 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Baricitinib Tablets, 1 mg and 2 mg. Aurobindo Pharma’s Baricitinib Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Olumiant Tablets manufactured by Eli Lilly and Company. Baricitinib Tablets […]

July 18, 2024


Aurobindo Receives FDA Approval for Posaconazole Delayed-Release Tablets, 100 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Posaconazole Delayed-Release Tablets, 100 mg. Aurobindo Pharma’s Posaconazole Delayed-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Noxafil Delayed-Release Tablets manufactured by Merck, Sharp & Dohme LLC. Posaconazole […]

July 18, 2024


Aurobindo Receives FDA Approval for Dutasteride and Tamsulosin Hydrochloride Capsules USP, 0.5 mg/0.4 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dutasteride and Tamsulosin Hydrochloride Capsules USP, 0.5 mg/0.4 mg. Aurobindo Pharma’s Dutasteride and Tamsulosin Hydrochloride Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Jalyn Capsules manufactured by Waylis […]

July 16, 2024


Aurobindo Receives FDA Approval for Levothyroxine Sodium Tablets USP, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Levothyroxine Sodium Tablets USP, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Aurobindo Pharma’s Levothyroxine Sodium Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Synthroid […]

June 18, 2024


Aurobindo Receives FDA Approval for Lidocaine Ointment USP, 5%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lidocaine Ointment USP, 5%. Aurobindo Pharma’s Lidocaine Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Lidocaine Ointment manufactured by Fougera Pharmaceuticals Inc. Lidocaine Ointment are indicated: For production […]

June 03, 2024


Aurobindo Receives FDA Approval for Tofacitinib Extended-Release Tablets, 11 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tofacitinib Extended-Release Tablets, 11 mg. Aurobindo Pharma’s Tofacitinib Extended-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Xeljanz XR Extended-Release Tablets manufactured by Pfizer Inc. Tofacitinib Extended-Release Tablets […]

May 10, 2024


Aurobindo Receives FDA Approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. Aurobindo Pharma’s Oseltamivir Phosphate for Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Tamiflu® for Oral Suspension manufactured by Hoffmann-La […]

April 29, 2024


Aurobindo Receives FDA Approval for Colchicine Capsules, 0.6 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Colchicine Capsules, 0.6 mg. Aurobindo Pharma’s Colchicine Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD),Mitigare Capsules manufactured by Hikma International Pharmaceuticals LLC. Colchicine Capsules are indicated for: Prophylaxis […]

April 10, 2024


Aurobindo Receives FDA Approval for Betamethasone Dipropionate Ointment USP, (Augmented), 0.05%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Ointment USP, (Augmented), 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Diprolene® Ointment manufactured by Organon LLC. Betamethasone Dipropionate Ointment are […]

March 21, 2024


Aurobindo Receives FDA Approval for Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. Aurobindo Pharma’s Desmopressin Acetate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), DDAVP Tablets manufactured by Ferring Pharmaceuticals, Inc. Desmopressin […]